Molecular Therapy - Nucleic Acids

Slides:



Advertisements
Similar presentations
Volume 17, Issue 9, Pages (September 2015)
Advertisements

Supplementary Figure 3 Antigen-specific responses are enhanced by stimulation in an in vitro stimulation (IVS) assay, as well as with stimulation using.
Gamma Delta T Cell Reconstitution Is Associated with Fewer Infections and Improved Event-Free Survival after Hematopoietic Stem Cell Transplantation for.
Molecular Therapy - Methods & Clinical Development
Engineering Human Peripheral Blood Stem Cell Grafts that Are Depleted of Naïve T Cells and Retain Functional Pathogen-Specific Memory T Cells  Marie Bleakley,
Volume 122, Issue 5, Pages (May 2002)
Volume 19, Issue 12, Pages (December 2011)
Depletion of Alloreactive Donor T Lymphocytes by CD95-Mediated Activation-Induced Cell Death Retains Antileukemic, Antiviral, and Immunoregulatory T Cell.
Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses by Giulia Nizzoli, Jana Krietsch, Anja Weick, Svenja.
Functionally Active HIV-Specific T Cells that Target Gag and Nef Can Be Expanded from Virus-Naïve Donors and Target a Range of Viral Epitopes: Implications.
CMV-, EBV- and ADV-Specific T Cell Immunity: Screening and Monitoring of Potential Third-Party Donors to Improve Post-Transplantation Outcome  Cinja Sukdolak,
Maintenance of HCV-specific T-cell responses in antibody-deficient patients a decade after early therapy by Nasser Semmo, Michaela Lucas, George Krashias,
Association of Cumulative Steroid Dose with Risk of Infection after Treatment for Severe Acute Graft-versus-Host Disease  Yayoi Matsumura-Kimoto, Yoshihiro.
Volume 79, Issue 6, Pages (March 2011)
Risk Factors and Utility of a Risk-Based Algorithm for Monitoring Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections in Pediatric Recipients.
Infectious Disease Following Kidney Transplant: Core Curriculum 2010
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation by Ann M.
Simultaneous Ex Vivo Expansion of Cytomegalovirus and Epstein-Barr Virus–Specific Cytotoxic T Lymphocytes Using B-Lymphoblastoid Cell Lines Expressing.
The Clinical Impact of Infection with Swine Flu (H1N109) Strain of Influenza Virus in Hematopoietic Stem Cell Transplant Recipients  Biju George, Patricia.
Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants by Georg.
Mature dendritic cells pulsed with freeze–thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4+ and CD8+ T lymphocyte.
HLA-A*0201+ Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients  Caroline Aspord, Marie-Therese Leccia, Dimitri Salameire,
Volume 22, Issue 6, Pages (June 2014)
Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell–depleted stem cell transplantation.
Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia  Guenther.
Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo by Suzanne M. McGoldrick, Marie E. Bleakley,
Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses by Cagan Gurer, Till.
CD134-Allodepletion Allows Selective Elimination of Alloreactive Human T Cells without Loss of Virus-Specific and Leukemia-Specific Effectors  Xupeng.
R. Handgretinger, X. Chen, M. Pfeiffer, M. Schumm, I. Mueller, T
Volume 22, Issue 2, Pages (February 2014)
Evaluation and Management of BK Virus-Associated Nephropathy Following Allogeneic Hematopoietic Cell Transplantation  Mihir Raval, Alison Gulbis, Catherine.
Volume 17, Issue 9, Pages (September 2009)
Cytomegalovirus-Specific Cytotoxic T Lymphocytes Can Be Efficiently Expanded from Granulocyte Colony-Stimulating Factor–Mobilized Hemopoietic Progenitor.
Application of the ELISPOT assay to the characterization of CD8+ responses to Epstein-Barr virus antigens by Jie Yang, Victor M. Lemas, Ian W. Flinn, Chris.
Inducible Caspase 9 Suicide Gene to Improve the Safety of Allodepleted T Cells after Haploidentical Stem Cell Transplantation  Siok-Keen Tey, Gianpietro.
Molecular Therapy - Oncolytics
Recovery of Varicella-Zoster Virus–Specific T Cell Immunity after T Cell–Depleted Allogeneic Transplantation Requires Symptomatic Virus Reactivation 
Partial T Cell-Depleted Allogeneic Stem Cell Transplantation following Reduced- Intensity Conditioning Creates a Platform for Immunotherapy with Donor.
Human CD8+ memory and EBV-specific T cells show low alloreactivity in vitro and in CD34+ stem cell–engrafted NOD/SCID/IL-2Rγcnull mice  Simone Thomas,
Preclinical toxicology of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for prostate cancer  Svend O Freytag, Yingshu Zhang,
The Clinical Impact of Infection with Swine Flu (H1N109) Strain of Influenza Virus in Hematopoietic Stem Cell Transplant Recipients  Biju George, Patricia.
Volume 22, Issue 3, Pages (March 2014)
HLA-A*0201+ Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients  Caroline Aspord, Marie-Therese Leccia, Dimitri Salameire,
Volume 18, Issue 4, Pages (April 2010)
Volume 19, Issue 11, Pages (November 2011)
Volume 17, Issue 8, Pages (August 2009)
Volume 92, Issue 4, Pages (October 2017)
Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor
Valder R Arruda, Patricia Favaro, Jonathan D Finn  Molecular Therapy 
Molecular Therapy - Methods & Clinical Development
A comparison of gene transfer and antigen-loaded dendritic cells for the generation of CD4+ and CD8+ cytomegalovirus-specific T cells in HLA-A2+ and HLA-A2−
Chapter 8 Myocarditis © 2014, Elsevier Inc., Willis, et.al., Cellular and Molecular Pathobiology of Cardiovascular Disease.
Protective Immunity Transferred by Infusion of Cytomegalovirus-Specific CD8+ T Cells within Donor Grafts: Its Associations with Cytomegalovirus Reactivation.
HIV-1 Vif: Counteracting Innate Antiretroviral Defenses
Volume 12, Issue 5, Pages (November 2005)
Volume 13, Issue 2, Pages (February 2006)
Volume 23, Issue 1, Pages (January 2015)
Diagnostic value of quantitative PCR for adenovirus detection in stool samples as compared with antigen detection and cell culture in haematopoietic stem.
Volume 18, Issue 9, Pages (September 2010)
Volume 8, Issue 2, Pages (August 2003)
Volume 22, Issue 1, Pages (January 2014)
Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide
Volume 8, Issue 7, Pages (March 1998)
Volume 22, Issue 3, Pages (March 2014)
Molecular Therapy - Oncolytics
Molecular Therapy - Nucleic Acids
Human Herpes Virus 6 Plasma DNA Positivity after Hematopoietic Stem Cell Transplantation in Children: an Important Risk Factor for Clinical Outcome  P.J.
Molecular Therapy - Nucleic Acids
Volume 88, Issue 6, Pages (December 2015)
Pretreatment of donor T cells with a c-Rel antagonist does not impair GVT activity. Pretreatment of donor T cells with a c-Rel antagonist does not impair.
Presentation transcript:

Molecular Therapy - Nucleic Acids Moving Successful Virus-specific T-cell Therapy for Hematopoietic Stem Cell Recipients to Late Phase Clinical Trials  Cliona Rooney, Ann Leen  Molecular Therapy - Nucleic Acids  Volume 1, (January 2012) DOI: 10.1038/mtna.2012.49 Copyright © 2012 American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 Relative frequency of viral infections after HSCT. Adv, adenovirus; BK, JC, KI, and WU (polyomaviruses); CMV, cytomegalovirus; H1N1, influenza strain Hemagglutinnin 1 Neuraminidase 1); HHV, human herpes virus; HSCT, hematopoietic stem cell transplant; HSV, herpes simplex virus; RSV, respiratory syncytial virus; VZV, varicella zoster virus. Molecular Therapy - Nucleic Acids 2012 1, DOI: (10.1038/mtna.2012.49) Copyright © 2012 American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Time line for original (complex) manufacture of T-cells specific for cytomegalovirus (CMV), Epstein-Barr virus (EBV), and adenoviruses (AdV). Establishment of the lymphoblastoid cell line (LCL) used as the antigen-presenting cell takes about 6 weeks. Once the LCL is established, the cytotoxic T-cell line (CTL) is initiated. Peripheral blood mononuclear cells (PBMCs) are cultured overnight to activate monocytes that are then transduced with an adenovirus vector expressing the pp65 protein from CMV (Ad5f35-pp65).They are then cultured for 9 days during which time, T-cells specific for virion proteins of the AdV and its CMV-pp65 transgene are activated. On day 9 and weekly thereafter, the T cells are restimulated with the autologous EBV-LCL transduced with Ad5f35-pp65. Interleukin (IL)-2 is added twice weekly from day 14. Sufficient EBV-specific T cells remain in the culture on day 9 to be reactivated by the EBV-LCL. After the third or fourth stimulation, sufficient T-cells specific for CMV, EBV, and AdV are cryopreserved for infusion and tested for sterility, identity by HLA typing, phenotype, lack of alloreactivity by Cr51 release assay, and specificity by γ-IFN ELIspot assay (a further 7–10 days). HLA, human leukocyte antigen; QC, quality control. Molecular Therapy - Nucleic Acids 2012 1, DOI: (10.1038/mtna.2012.49) Copyright © 2012 American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 Time line for simplified manufacture of antigen-specific T cells using plasmids or pepmixes. In the upper panel, peripheral blood mononuclear cells (PBMCs) are stimulated with autologous, mature dendritic cells nucleofected (Amaxa) with DNA plasmids expressing viral antigens.14 In the lower panel, PBMCs are directly stimulated with pepmixes (peptide libraries containing 15mers overlapping by 11 amino acids). In both cases, cells are stimulated in the presence of interleukin (IL)-4 and IL-7 in G-Rex culture devices, and expanded for 9–14 days. The T cells are then cryopreserved and tested for sterility, identity by HLA typing, phenotype, lack of alloreactivity by Cr51 release assay, and specificity by γ-IFN ELIspot assay. CTL, cytotoxic T-cell line; DC, dendritic cell; HLA, human leukocyte antigen; QC, quality control. Molecular Therapy - Nucleic Acids 2012 1, DOI: (10.1038/mtna.2012.49) Copyright © 2012 American Society of Gene & Cell Therapy Terms and Conditions